Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Last trade$6.72
Day change-$0.085 (-1.25%)
Day range$6.62 – $6.88
Volume218,360
Market cap$277M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$277.17M
Price / earnings
—
Price / book
0.65×
Price / sales
0.33×
EV / sales
0.51×
EV / EBITDA
8.83×
Profitability
Earnings per share
-$1.10
Return on assets
-5.26%
Return on equity
-10.48%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.55×
Current ratio
3.11×
Quick ratio
1.74×
Cash ratio
0.62×
Cash flow
Price / cash flow
65.59×
Price / free cash flow
—
Free cash flow
-$44.46M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OFIX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$207.86M
$210.93M
$196.71M
$219.91M
$205.63M
$203.12M
$193.65M
$215.66M
Cost of revenue
$61.32M
$61.23M
$57.16M
$63.57M
$57.11M
$63.59M
$72.03M
$66.82M
Gross profit
$146.55M
$149.71M
$139.55M
$156.34M
$148.52M
$139.53M
$121.62M
$148.84M
Selling, general and administrative
$125.33M
$138.03M
$134.91M
$136.75M
$148.1M
$136.49M
$132.98M
$136.48M
Research and development
$15.28M
$15.94M
$15.32M
$15.37M
$14.77M
$15.93M
$19.77M
$18.81M
Total operating expenses
$145M
$157.84M
$153.98M
$155.85M
$165.57M
$155.54M
$170.49M
$160.32M
Operating income
$1.55M
-$8.13M
-$14.44M
$494K
-$17.05M
-$16M
-$48.87M
-$11.48M
Interest expense
-$5.89M
-$6.09M
$0
-$4.35M
-$4.68M
-$3.95M
$0
-$14.92M
Income before taxes
-$5.25M
-$15M
-$20.83M
-$2.19M
-$22.26M
-$14.22M
-$52.13M
-$29.71M
Income taxes
$826K
$801K
$74K
$30K
$533K
-$142K
$961K
-$564K
Net income
-$6.07M
-$15.8M
-$20.91M
-$2.22M
-$22.8M
-$14.08M
-$53.09M
-$29.15M
Net income attributable to common shareholders
-$6.07M
-$15.8M
-$20.91M
-$2.22M
-$22.8M
-$14.08M
-$53.09M
-$29.15M
EBITDA
$19.11M
$9.01M
$2.81M
$17.29M
-$1.41M
$3.98M
$3.3M
$9.55M
Basic earnings per share
-$0.15
-$0.39
-$0.52
-$0.06
-$0.57
-$0.36
-$1.35
-$0.76
Diluted earnings per share
-$0.15
-$0.39
-$0.52
-$0.06
-$0.57
-$0.36
-$1.35
-$0.76
Recent news
Company coverage with links to the original publishers.
Orthofix reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.11 by 63.64%, but revenues of $207.8 million missed expectations by 1.25%. The stock has underperformed the market significantly, down 48.1% year-to-date versus the S&P 500's 7.8% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market near-term.
Artivion reported Q3 2026 earnings of $0.08 per share, missing the consensus estimate of $0.11 and down from $0.16 year-ago. The company beat revenue expectations at $123.79 million, up from $113.39 million year-over-year. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market. The Medical-Instruments industry ranks in the top 43% of Zacks industries. Peer company Orthofix is expected to report results on November 9 with anticipated earnings of $0.11 per share, down 45% year-over-year.
Orthofix (OFIX) shares surged 11% on investor optimism ahead of its third quarter 2026 financial results expected on November 9. The medical device maker is projected to report quarterly earnings of $0.11 per share (down 45% year-over-year) with revenues of $210.43 million (up 2.3%). However, analysts note the stock's recent gains may lack sustainability as consensus EPS estimates have remained unchanged over the past 30 days, and stocks typically require positive earnings estimate revisions to maintain upward momentum.
The global orthobiologics market is projected to grow from USD 6.68 billion in 2025 to USD 9.52 billion by 2031, with a CAGR of 6.17%. Growth is driven by rising osteoarthritis cases, sports-related injuries, and advancements in regenerative therapies including stem cell therapy and platelet-rich plasma treatments. North America leads the market while Asia-Pacific is the fastest-growing region.
Orthofix Medical reported Q2 2025 financial results, beating earnings estimates with $203.1 million in revenue, representing 2.3% year-over-year growth. The company saw segment gains in Bone Growth Therapies and Orthopedics, with positive free cash flow and continued new product execution.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.